Abivax (ABVX) Projected to Post Quarterly Earnings on Monday

Key Points

• Abivax is expected to report Q2 2026 results after the market closes on September 21, 2026. Analysts forecast a loss of $0.917 per share and revenue of approximately $0.799 million.
• Wall Street maintains a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $156.38, despite one sell rating.
• Abivax shares opened at $118.64, giving the clinical-stage biotechnology company a market capitalization of about $10.35 billion; institutional investors own 47.91% of its stock.

Abivax (NASDAQ:ABVX - Get Free Report) will likely be issuing its Q2 2026 results after the market closes on Monday, September 21st. Analysts expect Abivax to announce earnings of ($0.9170) per share and revenue of $0.7990 million for the quarter. Investors are encouraged to explore the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Monday, September 21, 2026 at 11:40 AM ET.

Abivax Stock Performance

NASDAQ ABVX opened at $118.64 on Monday. Abivax has a one year low of $69.81 and a one year high of $148.83. The company has a 50-day simple moving average of $124.83 and a 200-day simple moving average of $118.22. The firm has a market capitalization of $10.35 billion, a PE ratio of -22.77 and a beta of 0.96.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Abivax in a report on Friday, July 17th. Truist Financial upped their price objective on Abivax from $135.00 to $155.00 and gave the stock a "buy" rating in a research note on Thursday, July 2nd. Citizens Jmp reaffirmed a "market outperform" rating and issued a $187.00 target price on shares of Abivax in a research report on Wednesday, July 1st. Leerink Partners raised their target price on Abivax from $140.00 to $148.00 and gave the company an "outperform" rating in a research note on Tuesday, June 30th. Finally, HC Wainwright reissued a "buy" rating on shares of Abivax in a report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Abivax currently has a consensus rating of "Moderate Buy" and an average target price of $156.38.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Abivax by 661.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company's stock valued at $53,000 after acquiring an additional 344 shares in the last quarter. T. Rowe Price Investment Management Inc. bought a new stake in Abivax during the fourth quarter worth approximately $61,000. &PARTNERS bought a new stake in Abivax during the fourth quarter worth approximately $299,000. SmartHarvest Portfolios LLC acquired a new stake in Abivax in the fourth quarter worth approximately $326,000. Finally, Fox Run Management L.L.C. acquired a new stake in Abivax in the fourth quarter worth approximately $339,000. Institutional investors own 47.91% of the company's stock.

About Abivax

Abivax is a clinical-stage biotechnology company headquartered in Paris, France, focused on developing oral therapies for chronic inflammatory and immune-mediated diseases. Its lead investigational product is obefazimod, an oral small-molecule therapy designed to enhance the production of microRNA-124, a regulator of inflammatory pathways.

Obefazimod is being developed primarily for ulcerative colitis, a chronic inflammatory disease of the colon, and has also been evaluated in Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.